Welcome!

News Feed Item

Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics

LONDON, Aug. 27, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics

https://www.reportbuyer.com/product/2276220/Collaborative-RD-Terms--Agreements-in-Pharma-Biotech-and-Diagnostics.html

The Collaborative R&D Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the collaborative R&D deals and agreements entered into by the worlds leading life science companies.

The report provides a detailed understand and analysis of how and why companies enter collaborative R&D deals.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual collaborative R&D contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of collaborative R&D dealmaking and business activities.

The initial chapters of this report provide an orientation of collaborative R&D dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in collaborative R&D as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of collaborative R&D deals. The chapter includes numerous case studies to enable understanding of both pure collaborative R&D deals and multicomponent deals where collaborative R&D forms a part.

Chapter 4 provides a review of the leading collaborative R&D deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, signed by bigbiotech, most active bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive review of collaborative R&D financials for deals announced since 2009, including headline value, upfront, milestone payments and royalty rates by stage of development, providing both benchmark data and access to individual deal financials.

Chapters 6 and 7 provide a comprehensive listing of the top 50 bigpharma and bigbiotech companies with a brief summary followed by a comprehensive listing of collaborative R&D deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 8 provides a comprehensive and detailed review of collaborative R&D deals signed and announced since 2009 where a contract document is available. The chapter is organized by company A-Z, stage of development at signing, technologyand therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report also includes numerous table and figures that illustrate the trends and activities in collaborative R&D dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about collaborative R&D as an opportunity to participate in the commercialization of either candidate compounds in development or products already on the market.

Report scope

Collaborative R&D Terms and Agreements in Pharma, Biotech and Diagnostics is intended to provide the reader with an in-depth understanding of the collaborative R&D trends and structure of deals entered into by leading life science companies worldwide.

Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics includes:

Trends in collaborative R&D dealmaking in the biopharma industry since 2009
Analysis of collaborative R&D deal structure
Case studies of real-life collaborative R&D deals
Comprehensive listing of collaborative R&D deals since 2009
Access to collaborative R&D contract documents
Key financial benchmarks for headline, upfront, milestone and royalty rates
The leading collaborative R&D deals by value since 2009
Most active collaborative R&D dealmakers since 2009
The leading collaborative R&D partnering resources

In Collaborative R&D Terms and Agreements in Pharma, Biotech and Diagnostics available deals and contracts are listed by:

Company A-Z
Headline value
Therapeutic area
Technology type

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

The Collaborative R&D Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive access to available contract documents for licensing deals. Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How do milestone align with clinical stage development phases?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in collaborative R&D dealmaking

2.1. Introduction
2.2. Definition of collaborative R&D partnering
2.3. Success factors for collaborative R&D deals
2.4. When collaborative R&D can be useful
2.5. Attributes of collaborative R&D deals
2.6. Trends in collaborative R&D deals since 2009
2.7. The future of collaborative R&D deals

Chapter 3 – Overview of collaborative R&D deal structure

3.1. Introduction
3.2. Pure versus multi-component collaborative R&D deals
3.3. Pure collaborative R&D agreement structure
3.3.1. Example collaborative R&D agreements
3.3.1.a. Case study 1: Marinus Pharmaceuticals - NovaMedica – June 2013
3.3.1.b. Case study 2: Idenix Pharmaceuticals – Janssen Pharmaceuticals – January 2013
3.4. Collaborative R&D as part of a wider alliance agreement
3.4.1. Example collaborative R&D agreements and their licensing clauses
3.4.1.a. Case study 3: 4D Molecular Therapeutics – UniQure – January 2014
3.4.1.b. Case study 4: Kyowa Hakko Kirin – Ultragenyx Pharmaceuticals – September 2013
3.4.2. Example licensing option right clauses in collaborative R&D deals
3.4.2.a. Case study 5: Forest Laboratories - Trevena – May 2013
3.4.2.b. Case study 6: Abbvie – Receptos – March 2013

Chapter 4 – Leading collaborative R&D deals

4.1. Introduction
4.2. Top collaborative R&D deals by value
4.3. Most active collaborative R&D dealmakers
4.3.1 Most active collaborative R&D dealmakers by therapy
4.3.2. Most active collaborative R&D dealmakers by stage of development
4.4. Bigpharma collaborative R&D deal activity
4.4. Bigbiotech collaborative R&D deal activity

Chapter 5 – Collaborative R&D deal term benchmarks

5.1. Introduction
5.2. Collaborative R&D headline values
5.5.2. Collaborative R&D upfront payments
5.2.3. Collaborative R&D milestone payments
5.2.4. Collaborative R&D royalty rates

Chapter 6 – Bigpharma collaborative R&D deals

6.1. Introduction
6.2. How to use collaborative R&D deals
6.3. Big pharma collaborative R&D agreement listings

Chapter 7 – Bigbiotech collaborative R&D deals

7.1. Introduction
7.2. How to use collaborative R&D deals
7.3. Big biotech collaborative R&D agreement listings

Chapter 8 – Collaborative R&D contract directory 2009-2014

8.1. Introduction
8.2. Company A-Z
8.3. By therapy area
8.4. By stage of development at signing
8.5. By technology area

Appendices

Appendix – Resources
Appendix – Deal type definitions
Appendix 1 – Collaborative R&D dealmaking - by financial disclosure
Appendix 2 – Collaborative R&D - by companies A-Z
Appendix 3 – Collaborative R&D - by stage of development
Appendix 4 – Collaborative R&D - by therapeutic target
Appendix 5 – Collaborative R&D - by technology type

About Wildwood Ventures

Current Partnering
Current Agreements

TABLE OF FIGURES

Figure 1: Definition of collaborative R&D
Figure 2: Situations where collaborative R&D can prove useful
Figure 3: Key attributes of a collaborative R&D deal
Figure 4: Trends in collaborative R&D deal announcements, 2009-2014
Figure 5: Collaborative R&D deals signed at each phase of development, 2009-2014
Figure 6: Collaborative R&D deals by therapy area, 2009-2014
Figure 7: Collaborative R&D agreements – what should a contract include?
Figure 8: Components of the collaborative R&D deal structure
Figure 9: Top collaborative R&D deals by value since 2009
Figure 10: Most active collaborative R&D dealmakers 2009-2014
Figure 11: Most active collaborative R&D dealmakers 2009-2014 by therapy
Figure 12: Most active collaborative R&D dealmakers 2009-2014 – by stage of development
Figure 13: Bigpharma – top 50 – collaborative R&D deals 2009 to 2014
Figure 14: Bigpharma collaborative R&D deal frequency - 2009 to 2014
Figure 15: Bigbiotech – top 50 – collaborative R&D deals 2009 to 2014
Figure 16: Bigbiotech collaborative R&D deal frequency - 2009 to 2014
Figure 17: Collaborative R&D deal headline value distribution, US$million – discovery stage
Figure 18: Collaborative R&D deal headline value distribution, US$million – preclinical stage
Figure 19: Collaborative R&D deal headline value distribution, US$million – phase I stage
Figure 20: Collaborative R&D deal headline value distribution, US$million – phase II stage
Figure 21: Collaborative R&D deal headline value distribution, US$million – phase III stage
Figure 22: Collaborative R&D deal headline value distribution, US$million – regulatory stage
Figure 23: Collaborative R&D deal headline value distribution, US$million – marketed stage
Figure 24: Summary median Collaborative R&D headline value by stage of development, 2009-2014
Figure 25: Collaborative R&D deal upfront payment distribution, US$million – discovery stage
Figure 26: Collaborative R&D deal upfront payment distribution, US$million – preclinical stage
Figure 27: Collaborative R&D deal upfront payment distribution, US$million – phase I stage
Figure 28: Collaborative R&D deal upfront payment distribution, US$million – phase II stage
Figure 29: Collaborative R&D deal upfront payment distribution, US$million – phase III stage
Figure 30: Collaborative R&D deal upfront payment distribution, US$million – regulatory stage
Figure 31: Collaborative R&D deal upfront payment distribution, US$million – marketed stage
Figure 32: Summary median collaborative R&D upfront payments by stage of development, 2009-2014
Figure 33: Collaborative R&D deal milestone distribution, US$million – discovery stage
Figure 34: Collaborative R&D deal milestone distribution, US$million – preclinical stage
Figure 35: Collaborative R&D deal milestone distribution, US$million – phase I stage
Figure 36: Collaborative R&D deal milestone distribution, US$million – phase II stage
Figure 37: Collaborative R&D deal milestone distribution, US$million – phase III stage
Figure 38: Collaborative R&D deal milestone distribution, US$million – regulatory stage
Figure 39: Collaborative R&D deal milestone distribution, US$million – marketed stage
Figure 40: Collaborative R&D deals with royalty rates, %
Figure 41: Collaborative R&D deal royalty rate distribution, US$million – discovery stage
Figure 42: Collaborative R&D deal royalty rate distribution, US$million – preclinical stage
Figure 43: Collaborative R&D deal royalty rate distribution, US$million – phase I stage
Figure 44: Collaborative R&D deal royalty rate distribution, US$million – phase II stage
Figure 45: Collaborative R&D deal royalty rate distribution, US$million – phase III stage
Figure 46: Collaborative R&D deal royalty rate distribution, US$million – regulatory stage
Figure 47: Collaborative R&D deal royalty rate distribution, US$million – marketed stage
Figure 48: Summary median collaborative R&D royalty rate by stage of development, 2009-2014
Figure 49: Online partnering resources
Figure 50: Deal type definitions

Read the full report:
Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics

https://www.reportbuyer.com/product/2276220/Collaborative-RD-Terms--Agreements-in-Pharma-Biotech-and-Diagnostics.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The current age of digital transformation means that IT organizations must adapt their toolset to cover all digital experiences, beyond just the end users’. Today’s businesses can no longer focus solely on the digital interactions they manage with employees or customers; they must now contend with non-traditional factors. Whether it's the power of brand to make or break a company, the need to monitor across all locations 24/7, or the ability to proactively resolve issues, companies must adapt to...
"We focus on composable infrastructure. Composable infrastructure has been named by companies like Gartner as the evolution of the IT infrastructure where everything is now driven by software," explained Bruno Andrade, CEO and Founder of HTBase, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"Tintri focuses on the Ops side of the DevOps, which basically is pushing more and more of the accessibility of the infrastructure to the developers and trying to get behind the scenes," explained Dhiraj Sehgal of Tintri in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Hardware virtualization and cloud computing allowed us to increase resource utilization and increase our flexibility to respond to business demand. Docker Containers are the next quantum leap - Are they?! Databases always represented an additional set of challenges unique to running workloads requiring a maximum of I/O, network, CPU resources combined with data locality.
For organizations that have amassed large sums of software complexity, taking a microservices approach is the first step toward DevOps and continuous improvement / development. Integrating system-level analysis with microservices makes it easier to change and add functionality to applications at any time without the increase of risk. Before you start big transformation projects or a cloud migration, make sure these changes won’t take down your entire organization.
Cloud promises the agility required by today’s digital businesses. As organizations adopt cloud based infrastructures and services, their IT resources become increasingly dynamic and hybrid in nature. Managing these require modern IT operations and tools. In his session at 20th Cloud Expo, Raj Sundaram, Senior Principal Product Manager at CA Technologies, will discuss how to modernize your IT operations in order to proactively manage your hybrid cloud and IT environments. He will be sharing bes...
Artificial intelligence, machine learning, neural networks. We’re in the midst of a wave of excitement around AI such as hasn’t been seen for a few decades. But those previous periods of inflated expectations led to troughs of disappointment. Will this time be different? Most likely. Applications of AI such as predictive analytics are already decreasing costs and improving reliability of industrial machinery. Furthermore, the funding and research going into AI now comes from a wide range of com...
In this presentation, Striim CTO and founder Steve Wilkes will discuss practical strategies for counteracting fraud and cyberattacks by leveraging real-time streaming analytics. In his session at @ThingsExpo, Steve Wilkes, Founder and Chief Technology Officer at Striim, will provide a detailed look into leveraging streaming data management to correlate events in real time, and identify potential breaches across IoT and non-IoT systems throughout the enterprise. Strategies for processing massive ...
SYS-CON Events announced today that GrapeUp, the leading provider of rapid product development at the speed of business, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company, specialized in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market acr...
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devic...
SYS-CON Events announced today that Ayehu will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on October 31 - November 2, 2017 at the Santa Clara Convention Center in Santa Clara California. Ayehu provides IT Process Automation & Orchestration solutions for IT and Security professionals to identify and resolve critical incidents and enable rapid containment, eradication, and recovery from cyber security breaches. Ayehu provides customers greater control over IT infras...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
SYS-CON Events announced today that MobiDev, a client-oriented software development company, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software company that develops and delivers turn-key mobile apps, websites, web services, and complex software systems for startups and enterprises. Since 2009 it has grown from a small group of passionate engineers and business...
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
What's the role of an IT self-service portal when you get to continuous delivery and Infrastructure as Code? This general session showed how to create the continuous delivery culture and eight accelerators for leading the change. Don Demcsak is a DevOps and Cloud Native Modernization Principal for Dell EMC based out of New Jersey. He is a former, long time, Microsoft Most Valuable Professional, specializing in building and architecting Application Delivery Pipelines for hybrid legacy, and cloud ...